Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

FGFR fusion

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related biomarkers:

‹

FGFR mutation (21)

FGFR translocation (1)

FGFR wild-type (0)

FGFR mutation (21)

FGFR translocation (1)

FGFR wild-type (0)

›

FGFR fusion	Pancreatic Cancer	FGFR fusion	Pancreatic Cancer	pemigatinib Sensitive: C2 – Inclusion Criteria pemigatinib Sensitive : C2	pemigatinib Sensitive: C2 – Inclusion Criteria pemigatinib Sensitive : C2
FGFR fusion	Urothelial Cancer	FGFR fusion	Urothelial Cancer	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3
FGFR fusion	Urothelial Cancer	FGFR fusion	Urothelial Cancer	erdafitinib + JNJ-63723283 Sensitive: C3 – Early Trials erdafitinib + JNJ-63723283 Sensitive : C3	erdafitinib + JNJ-63723283 Sensitive: C3 – Early Trials erdafitinib + JNJ-63723283 Sensitive : C3
FGFR fusion	Cholangiocarcinoma	FGFR fusion	Cholangiocarcinoma	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3
FGFR fusion	Urothelial Cancer	FGFR fusion	Urothelial Cancer	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3
FGFR fusion	Non Small Cell Lung Cancer	FGFR fusion	Non Small Cell Lung Cancer	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3
FGFR fusion	Astrocytoma	FGFR fusion	Astrocytoma	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3
FGFR fusion	Uterine Cancer	FGFR fusion	Uterine Cancer	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3
FGFR fusion	Gallbladder Cancer	FGFR fusion	Gallbladder Cancer	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3
FGFR fusion	Head and Neck Cancer	FGFR fusion	Head and Neck Cancer	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3	pemigatinib Sensitive: C3 – Early Trials pemigatinib Sensitive : C3
FGFR fusion	Glioblastoma	FGFR fusion	Glioblastoma	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3
FGFR fusion	Pancreatic Cancer	FGFR fusion	Pancreatic Cancer	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3
FGFR fusion	Salivary Gland Cancer	FGFR fusion	Salivary Gland Cancer	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3
FGFR fusion	Cholangiocarcinoma	FGFR fusion	Cholangiocarcinoma	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3	erdafitinib Sensitive: C3 – Early Trials erdafitinib Sensitive : C3
FGFR fusion	Solid Tumor	FGFR fusion	Solid Tumor	ABSK121 Sensitive: D – Preclinical ABSK121 Sensitive : D	ABSK121 Sensitive: D – Preclinical ABSK121 Sensitive : D